What are the most common side effects of PEGINTERFERON BETA-1A?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for PEGINTERFERON BETA-1A. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is PEGINTERFERON BETA-1A the same as Plegridy Pen?

Plegridy Pen is a brand name for PEGINTERFERON BETA-1A. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

PEGINTERFERON BETA-1A

Q: What is PEGINTERFERON BETA-1A used for?

PEGINTERFERON BETA-1A (brand name Plegridy Pen) is a Other indicated for 1 INDICATIONS AND USAGE PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease.

Q: How does PEGINTERFERON BETA-1A work?

PEGINTERFERON BETA-1A works through the following mechanism: 12.1 Mechanism of Action The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown..

Other

Brand names: Plegridy Pen, Plegridy

Subcutaneous, Intramuscular

Mechanism of Action

12.1 Mechanism of Action The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown.

Indications

1 INDICATIONS AND USAGE PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

Contraindications

• 4 CONTRAINDICATIONS PLEGRIDY is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon
• or any other component of PLEGRIDY [see Warnings and Precautions ( 5.3 )] . History of hypersensitivity to natural or recombinant interferon beta or peginterferon
• or any other component of PLEGRIDY ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Hepatic injury: monitor liver function tests; monitor patients for signs and symptoms of hepatic injury; consider discontinuation of PLEGRIDY if hepatic injury occurs ( 5
2 ) Anaphylaxis and other allergic reactions: Discontinue PLEGRIDY if a serious allergic reaction occurs ( 5
The incidence of serious events related to depression and suicidal ideation was similar and less than 1% in both groups
3 Anaphylaxis and Other Allergic Reactions Serious allergic reactions are rare complications of treatment with interferon beta; anaphylaxis has been reported with use of PLEGRIDY in the postmarketing setting

Known Side Effects

11 documented side effects by frequency

Fatigue

>10%

Nausea

>10%

Headache

1-10%

Rash

1-10%

Itching

1-10%

Fever

1-10%

Diarrhea

0.1-1%

Vomiting

0.1-1%

Weakness

0.1-1%

Insomnia

0.1-1%

Shortness of Breath

0.1-1%

Community Discussions

No community discussions found for PEGINTERFERON BETA-1A yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → PEGINTERFERON BETA-1A openFDA label JSON → PEGINTERFERON BETA-1A FAERS adverse-event reports → PEGINTERFERON BETA-1A ClinicalTrials.gov → completed Phase 2+ trials of PEGINTERFERON BETA-1A

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Subcutaneous, Intramuscular